from 10:30 a.m. to 12:30 p.m. A portion of the public meeting will be closed and is tentatively scheduled from 2 p.m. to 5 p.m. The agenda is subject to change as priorities dictate. Please check the NBSB Web site for the most up-to-date information on the meeting.

**ADDRESSES:** Omni Shoreham Hotel, Palladian Ballroom, 2500 Calvert Street NW. (at Connecticut Ave.) Washington, District of Columbia 20008. To attend by teleconference, call 1–(866) 395–4129, pass-code “ASP.” Please call 15 minutes prior to the beginning of the conference call to facilitate attendance. Pre-registration is required for in person public attendance. Individuals who wish to attend the meeting in person should send an email to NBSB@HHS.GOV with “NBSB Registration” in the subject line.

**FOR FURTHER INFORMATION CONTACT:**
MacKenzie Robertson, Acting Executive Director, NBSB, Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services; (202) 260–0447; NBSB@HHS.GOV.

**SUPPLEMENTARY INFORMATION:** Pursuant to section 319M of the Public Health Service Act (42 U.S.C. 247d–7f) and section 222 of the Public Health Service Act (42 U.S.C. 217a), the Department of Health and Human Services established the National Biodefense Science Board. The Board shall provide expert advice and guidance to the Secretary on scientific, technical, and other matters of special interest to the Department of Health and Human Services regarding current and future chemical, biological, nuclear, and radiological agents, whether naturally occurring, accidental, or deliberate. The Board may also provide advice and guidance to the Secretary and/or the Assistant Secretary for Preparedness and Response on other matters related to public health emergency preparedness and response.

A portion of this public meeting will be dedicated to swearing in of the new task and deliberations on the PHEMCE SIP. The Board will also be asked to review and evaluate the 2012 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan (SIP). Until a final document is approved by the Secretary of the Department of Health and Human Services (HHS), the development of PHEMCE SIP requires consideration and discussion of procurement-sensitive information that should not be released to the public prior to the Secretary’s final decision. Premature public disclosure of the draft PHEMCE SIP would limit the Secretary’s decision-making ability to effectively prioritize HHS expenditures on critical medical countermeasures. Therefore, the Board’s deliberations on the new task will be conducted in closed session in accordance with provisions set forth under exemption 9(B) of the Government in Sunshine Act, 5 U.S.C. section 552(b)(c), and with approval by the Assistant Secretary for Preparedness and Response.

**Availability of Materials:** The meeting agenda and materials will be posted on the NBSB Web site at http://www.phe.gov/Preparedness/legal/boards/nbsb/Pages/default.aspx prior to the meeting.

**Procedures for Providing Public Input:** Any member of the public providing oral comments at the meeting must sign in at the registration desk and provide his/her name, address, and affiliation. All written comments must be received prior to January 26, 2012 and should be sent by email to NBSB@HHS.GOV with “NBSB Public Comment” as the subject line. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should email NBSB@HHS.GOV.


Nicole Lurie,
Assistant Secretary for Preparedness and Response.

**BILLING CODE 4150–37–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2011–N–0454]

**Privacy Act of 1974; Report of an Altered System of Records, Including Addition of Routine Uses to an Existing System of Records; Bioresearch Monitoring Information System**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of an altered system of records.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an alteration to an existing System of Records (System) titled “Bioresearch Monitoring Information System, HHS/FDA” (System No. 09–10–0010). Among other updates, this alteration adds new routine uses for disclosures of certain relevant information to Agencies, authorities, and organizations with responsibilities related to clinical investigations and/or clinical investigators; persons who require access to records to perform services for FDA; and individual research subjects.

**DATES:** This notice will be effective without further notice on February 8, 2012 unless modified by a subsequent notice making changes in response to public comments. FDA invites comments on all parts of the systems notice. Comments must be received on or before February 8, 2012. See ADDRESSES for information about submission of comments.

**ADDRESSES:** You may submit comments identified by Docket No. FDA–2011–N–0454 by any of the following methods:

**Electronic Submissions**
Submit electronic comments in the following way:

**Written Submissions**
Submit written submissions in the following ways:
- Fax: (301) 827–6870.
- Mail/Hand delivery/Courier (for paper or CD-ROM submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Instructions: All submissions received must include the Agency name and Docket No. FDA–2011–N–0454 for this notice. All comments received may be posted without change to http://www.regulations.gov, including any personal information provided. For additional information on submitting comments, see the “Comments” heading of the SUPPLEMENTARY INFORMATION section of this document.

**Docket:** For access to the docket to read background documents or comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:**
Kathleen E. Pflaender, Office of Good Clinical Practice, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring, MD 20993–0002, (301) 796–8340.

**SUPPLEMENTARY INFORMATION:**

I. Background

The Bioresearch Monitoring Information System provides controls to
ensure that clinical investigators meet the requirements of the relevant statutes and regulations governing FDA-regulated products. This System also supports the effective performance of activities necessary for the conduct of FDA’s bioresearch monitoring program.

II. Description of Changes to System of Records

We have changed, or altered, the Bioresearch Monitoring Information System as follows:

(a) General necessary updates to make the System current (e.g., adding the Center for Tobacco Products and the Office of Good Clinical Practice, updating addresses and revising citations).

(b) Adding to the categories of records in the System: clinical investigator financial arrangements with or interests in a study sponsor, because this information may be included in this System.

(c) Deleting an unnecessary routine use authorizing disclosure to congressional offices in response to inquiries from constituents who authorize disclosure by written consent. This routine use is unnecessary because the Privacy Act and FDA regulations permit disclosure upon prior written consent by the individual who is the subject of the records. (5 U.S.C. 552a(b), 21 CFR 21.70(a)(2) and 21.72).

(d) Amending part 1 of former routine use 1 to provide for disclosure to Federal, State, and local Agencies; government institutions; State licensing authorities; foreign governments/Agencies; international organizations; and non-governmental regulatory bodies of a foreign country. Such disclosure must be relevant to that entity’s oversight, investigative, regulatory, licensing, or enforcement responsibilities for clinical investigations and/or clinical investigators. This includes any referrals related to potential violations of law, as had been provided for under part 1 of former routine use 1 (routine use 1).

(e) Amending part 2 of former routine use 1 to provide for disclosure to sponsors, institutional review boards, and other non-government entities if the information disclosed is relevant to the receiving entity’s responsibility for the initiation, oversight, monitoring, compliance, or other regulatory requirement associated with the conduct of clinical investigations or oversight of a clinical investigator (routine use 2).

(f) Providing for disclosure to a research subject of information from a research misconduct proceeding that may have implications for that subject’s rights, safety, or welfare, or participation in a research study (routine use 3).

(g) Providing for disclosure to the public of information related to a clinical investigator’s financial arrangements with or interests in a study sponsor, to the extent disclosure is not an unwarranted invasion of personal privacy or is not otherwise protected from disclosure under FDA’s regulations or applicable statutes (routine use 4).

(h) Providing for disclosure to the public of regulatory information and/or correspondence, including untitled letters, Notice of Initiation of Disqualification Proceedings and Opportunity to Explain letters, Notice of Opportunity for Hearing letters, and warning letters issued to clinical investigators, and summary information from inspections of clinical investigators involved in FDA-regulated research, to the extent disclosure is not an unwarranted invasion of personal privacy or is not otherwise protected from disclosure under FDA’s regulations or applicable statutes (routine use 5).

(i) Providing for disclosure to persons who require access to records in order to perform services for FDA, such as serving on FDA research misconduct inquiry committees (routine use 6).

(j) Providing for disclosure to the appropriate Federal Agencies and HHS contractors in responding to a breach of the security or confidentiality of information in this System (routine use 7).

III. Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. The following is a copy of the altered System of Records, FDA invites comments on all parts of the System of Records (see section III of this document for information about submission of comments):

System No. 09–10–0010
SYSTEM NAME
Bioresearch Monitoring Information System, HHS/FDA.
SECURITY CLASSIFICATION
None.

SYSTEM LOCATIONS

Center for Biologics Evaluation and Research, Office of Compliance and Biologics Quality, Bioresearch Monitoring Team (refer to http://www.fda.gov for address specifics).

Center for Devices and Radiological Health, Office of Compliance, Division of Bioresearch Monitoring (refer to http://www.fda.gov for address specifics).

Center for Drug Evaluation and Research, Office of Compliance, Division of Scientific Investigations (refer to http://www.fda.gov for address specifics).

Center for Food Safety and Applied Nutrition, Office of Food Additive Safety, (refer to http://www.fda.gov for address specifics).

Office of Regulatory Affairs, Office of Enforcement (refer to http://www.fda.gov for address specifics), and Regional Field Offices (refer to http://www.fda.gov for address specifics).

Center for Tobacco Products (refer to http://www.fda.gov for address specifics).

Center for Veterinary Medicine, Division of Compliance, Bioresearch Monitoring Program (refer to http://www.fda.gov for address specifics).


CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM

This notice applies to clinical investigators who are conducting, or have conducted, clinical investigations of products regulated by FDA.

CATEGORIES OF RECORDS IN THE SYSTEM

This system includes records, regardless of format (e.g., electronic, hard copy, scanned), pertaining to clinical investigators who conduct research of products regulated by FDA, for example a clinical investigation that supports an application for a research or marketing permit for an FDA-regulated product. Records contain name, education, professional qualifications and background, and information on studies conducted. Records that contain information about certain financial arrangements with or interests in study sponsors may also be included in this system.

This system also contains records created or collected during inspections or investigations of clinical investigators for possible violations of statutes or regulations governing clinical investigations of FDA-regulated products.
AUTHORITY FOR MAINTENANCE OF THE SYSTEM


PURPOSES

The purposes of this system are to:

1. Support regulatory or procedural controls to ensure that clinical investigators meet requirements of the relevant statutes and regulations governing clinical investigations of FDA-regulated products.

2. Support the effective performance of activities necessary for the conduct of the FDA’s bioresearch monitoring program.

ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES

The Privacy Act lists the conditions of disclosure under 5 U.S.C. 552a(b).

Among the permitted disclosures is, “to those officers and employees of the Agency which maintains the record who have a need for the record in the performance of their duties” (5 U.S.C. 552a(b)(1)). For this system of records, this would include disclosure to appropriate FDA and Department of Health and Human Services (HHS) employees.

Permitted disclosures also include routine uses that are listed in the notice of the system of records. (See 5 U.S.C. 552a(b)(3)). The Privacy Act defines “routine use” as “with respect to the disclosure of a record, the use of such record for a purpose which is compatible with the purpose for which it was collected” (5 U.S.C. 552a(a)(7)).

See also FDA’s Privacy Act Record Systems regulations, defining “routine use” as, “use outside the Department of Health and Human Services that is compatible with the purpose for which the records were collected and described in the [System of Records] notice * * *.” (21 CFR 21.20(b)(5)).

The routine uses for this system of records are listed in the following numbered items.

1. Disclosure may be made to Federal, State, and local Agencies; government institutions; state licensing authorities; foreign governments/Agencies; international organizations; and non-governmental regulatory bodies of a foreign country. Such disclosure must be relevant to that entity’s oversight, investigative, regulatory, licensing, or enforcement responsibilities for clinical investigations and/or clinical investigators. This includes referrals for investigation and possible enforcement action to the U.S. Department of Justice and other appropriate Agencies, authorities, and organizations.

2. Disclosure may be made to sponsors, institutional review boards, and other non-government entities if the information disclosed is relevant to the receiving entity’s responsibility for the initiation, oversight, monitoring, compliance, or other regulatory requirement associated with the conduct of clinical investigations and/or oversight of clinical investigators.

3. Disclosure may be made to an individual research subject of information obtained or developed through a research misconduct proceeding if, in FDA’s judgment, the information may have implications for that subject’s rights, safety, or welfare, or participation in a research study.

4. Disclosure may be made to the public of information related to a clinical investigator’s financial arrangements with or interest in a study sponsor, to the extent disclosure is not an unwarranted invasion of personal privacy or is not otherwise protected from disclosure under FDA’s regulations or applicable statutes. Examples of the financial arrangements that FDA may disclose include but are not limited to outcome payments (i.e., where the payment to the clinical investigator is dependent on the outcome of the study) and proprietary interests (e.g., where the clinical investigator holds a patent).

5. Disclosure may be made to the public of regulatory information and/or correspondence, including untitled letters, Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE) letters, Notice of Opportunity for Hearing (NOOH) letters, and warning letters issued to clinical investigators, and summary information from inspections of clinical investigators, to the extent disclosure is not an unwarranted invasion of personal privacy or is not otherwise protected from disclosure under FDA’s regulations or applicable statutes.

6. Disclosure may be made to persons who require access to the records to perform services for FDA, for example, persons appointed to serve on FDA research misconduct inquiry committees or investigative committees, and FDA contractors, if such persons need access to the records to perform their assigned task. Provided, however, in each case FDA determines whether limitations on disclosures or confidentiality agreements are needed to protect the privacy of respondents, complainants, witnesses, research subjects or others who may be identified in the records to be disclosed; and FDA determines that the disclosure is for a purpose compatible with the purpose for which FDA collected the records.

7. Disclosure may be made to appropriate Federal Agencies and HHS contractors that have a need to know the information for the purpose of assisting the Department’s efforts to respond to a suspected or confirmed breach of the security or confidentiality of information maintained in this system of records, and the information disclosed is relevant and necessary for that assistance.

8. Disclosure may be made to the U.S. Department of Justice (DOJ) when: (a) the Agency or any component thereof; or (b) any employee of the Agency in his or her official capacity; or (c) any employee of the Agency in his or her individual capacity where the DOJ has agreed to represent the employee; or (d) the United States Government, is a party to litigation or has an interest in such litigation and, by careful review, the Agency determines that the records are both relevant and necessary to the litigation and the use of such records by the DOJ is therefore deemed by the Agency to be for a purpose that is compatible with the purpose for which the Agency collected the records.

9. Disclosure may be made to a court or other tribunal, when: (a) The Agency or any component thereof; or (b) any employee of the Agency in his or her official capacity; or (c) any employee of the Agency in his or her individual capacity where the DOJ has agreed to represent the employee; or (d) the United States Government, is a party to the proceeding or has an interest in such proceeding and, by careful review, the Agency determines that the records are both relevant and necessary to the proceeding and the use of such records is therefore deemed by the Agency to be, for a purpose that is compatible with the purpose for which the Agency collected the records.

POLICIES AND PRACTICES FOR STORING, RETRIEVING, ACCESSING, RETAINING, AND DISPOSING OF RECORDS IN THE SYSTEM

STORAGE:

Files may be maintained in various formats including hard copy paper in manual files, microfilm, magnetic disk or tape, computer disks, hard drives,
and file servers and other types of data storage devices.

RETRIEVABILITY:
Records may be indexed by name or code number, but can be retrieved by manual or computer search of the case-tracking system using the name of the individual.

SAFEGUARDS:
1. Authorized users:
Records in FDA’s system are available to the Commissioner of Food and Drugs, FDA’s System Managers, and to other appropriate FDA and HHS officials when there is a need to know in the performance of their duties. All authorized users are informed that the records are confidential and are not to be further disclosed.

2. Procedural safeguards:
Access is strictly controlled by FDA’s System Managers in compliance with the Privacy Act and this system notice. Access to the records is limited to ensure confidentiality. All questions and inquiries from any party should be addressed to FDA’s Office of Good Clinical Practice.

3. Physical safeguards:
All records (such as diskettes, computer listings, or documents) are kept in a secured area, locked rooms, and locked building. The facility has a 24-hour guard service, and access to the building is further controlled by an operational card key system. Access to the files, which are generally hard copy, are limited to a subset of persons with general access to the building. Access to individual offices is controlled by simplex locks. Records are kept in locked file cabinets in a room that is locked during non-working hours. Access to this room is restricted to specific personnel. Access to computer files is strictly limited through passwords and user-invisible encryption. Special measures commensurate with the sensitivity of the record are taken to prevent unauthorized copying or disclosure of the records.

RETENTION AND DISPOSAL:
The records are maintained in accordance with FDA’s Records Control Schedule, applicable General Records Schedule (accessions), and disposition schedule approved by the National Archives and Records Administration (cases).

SYSTEM MANAGERS AND ADDRESSES:
Division of Inspections and Surveillance. Center for Biologics Evaluation and Research, Office of Compliance and Biologics Quality (refer to http://www.fda.gov for address specifics).

Division of Bioresearch Monitoring, Center for Devices and Radiological Health, Office of Compliance (refer to http://www.fda.gov for address specifics).

Division of Scientific Investigations, Center for Drug Evaluation and Research, Office of Compliance (refer to http://www.fda.gov for address specifics).

Office of Food Additive Safety, Center for Food Safety and Applied Nutrition (refer to http://www.fda.gov for address specifics).

Office of Enforcement, Office of Regulatory Affairs (refer to http://www.fda.gov for address specifics), and Regional Field Offices (refer to http://www.fda.gov for address specifics).

Center for Tobacco Products (refer to http://www.fda.gov for address specifics).

Division of Compliance, Center for Veterinary Medicine, Bioresearch Monitoring Program (refer to http://www.fda.gov for address specifics).


NOTIFICATION PROCEDURES:
In accordance with 21 CFR part 21 subpart D, an individual may submit a request to the FDA Privacy Act Coordinator, with a notarized signature, to confirm whether records exist about that individual. Requests should be directed to the FDA Privacy Act Coordinator (refer to http://www.fda.gov for the address specifics). Investigative records are exempt from this provision (see the following sentences: Records Exempted from Certain Provisions of the Act). In addition, some records may be exempt under 5 U.S.C. 552a(d)(5) if they are “compiled in reasonable anticipation of a civil action or proceeding.”

RECORD SOURCE CATEGORIES:
Individual on whom the record is maintained. Some material is obtained from third parties (e.g., a study sponsor, publication, or institutional review board), or is developed by FDA.

RECORDS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT:
Investigatory records compiled for law enforcement purposes in this system are exempt from the notification, access, correction and amendment provisions of the Privacy Act (21 CFR 21.61).


Leslie Kux,
Acting Assistant Commissioner for Policy.

[FR Doc. 2012–114 Filed 1–6–12; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[USCG–2011–0975]

National Maritime Security Advisory Committee; Meeting

AGENCY: Coast Guard, DHS.

ACTION: Notice of Federal Advisory Committee Meeting.

SUMMARY: The National Maritime Security Advisory Committee (NMSAC) will meet on January 18–19, 2012 in Washington, DC to discuss various issues relating to national maritime security. This meeting will be open to the public.

DATES: The Committee will meet on Wednesday, January 18, 2012 from 9 a.m. to 3 p.m. and Thursday, January 19, 2012 from 9 a.m. to 12 p.m. This